Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Jun;17(6):713–717. doi: 10.1111/j.1365-2125.1984.tb02408.x

The influence of naloxone on the circulatory effects of captopril.

P C Rubin, J A Millar, S Sturani, C Lawrie, J L Reid
PMCID: PMC1463417  PMID: 6331480

Abstract

The fall in blood pressure produced by captopril is not accompanied by a compensatory tachycardia. Angiotensin converting enzyme may participate in the metabolism of endogenous opioids and these substances can lower blood pressure without reflex tachycardia. It is therefore possible that the hypotensive effect of captopril involves an action on endogenous opioid metabolism. The influence of naloxone, an opiate receptor antagonist, on the cardiovascular effects of captopril has been studied in nine normal volunteers. Mean blood pressure following a 70 degrees head up tilt 1.5 h after captopril was significantly lower than following placebo, but the blood pressure following the combination of captopril and naloxone differed from neither the placebo nor the captopril values. Blood pressures (mm Hg) were: placebo 97.7 +/- 5.9; captopril 83.3 +/- 14.2; captopril + naloxone 89.6 +/- 11.8. Heart rate (beats/min) following a 70 degrees head up tilt at 1.5 h was the same on all three treatments: placebo 83.4 +/- 21.1; captopril 83.3 +/- 16.5; captopril + naloxone 83.6 +/- 11.8. Maximum systolic blood pressure achieved during isometric exercise following captopril + naloxone was intermediate between, and did not differ significantly from, pressures obtained on the other two treatment days. We conclude that co-administration of naloxone may attenuate the effect of captopril on blood pressure and that endogenous opioids could be involved in the actions of this drug.

Full text

PDF
713

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold M. A., Carr D. B., Togasaki D. M., Pian M. C., Martin J. B. Caffeine stimulates beta-endorphin release in blood but not in cerebrospinal fluid. Life Sci. 1982 Sep 6;31(10):1017–1024. doi: 10.1016/0024-3205(82)90174-6. [DOI] [PubMed] [Google Scholar]
  2. Arregui A., Lee C. M., Emson P. C., Iversen L. L. Separation of human brain angiotensin-converting enzyme from enkephalin-degrading activity. Eur J Pharmacol. 1979 Oct 26;59(1-2):141–144. doi: 10.1016/0014-2999(79)90037-2. [DOI] [PubMed] [Google Scholar]
  3. Chiknas S. G. A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum. Clin Chem. 1979 Jul;25(7):1259–1262. [PubMed] [Google Scholar]
  4. Cody R. J., Jr, Tarazi R. C., Bravo E. L., Fouad F. M. Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med. 1978 Nov;55(5):453–459. doi: 10.1042/cs0550453. [DOI] [PubMed] [Google Scholar]
  5. Cushman D. W., Cheung H. S. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 1971 Jul;20(7):1637–1648. doi: 10.1016/0006-2952(71)90292-9. [DOI] [PubMed] [Google Scholar]
  6. Hatton R., Clough D. P. Captopril interferes with neurogenic vasoconstriction in the pithed rat by angiotensin-dependent mechanisms. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):116–123. doi: 10.1097/00005344-198201000-00019. [DOI] [PubMed] [Google Scholar]
  7. Henry D. P., Starman B. J., Johnson D. G., Williams R. H. A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci. 1975 Feb 1;16(3):375–384. doi: 10.1016/0024-3205(75)90258-1. [DOI] [PubMed] [Google Scholar]
  8. Millar J. A., McGrath B. P., Matthews P. G., Johnston C. I. Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients. Clin Sci (Lond) 1981 Jul;61(1):75–83. doi: 10.1042/cs0610075. [DOI] [PubMed] [Google Scholar]
  9. Petty M. A., Reid J. L. The effect of opiates on arterial baroreceptor reflex function in the rabbit. Naunyn Schmiedebergs Arch Pharmacol. 1982 Jun;319(3):206–211. doi: 10.1007/BF00495866. [DOI] [PubMed] [Google Scholar]
  10. Roulston J. E., MacGregor G. A. The measurement of angiotensin-converting enzyme in subjects receiving captopril. N Engl J Med. 1980 Aug 14;303(7):397–397. doi: 10.1056/NEJM198008143030717. [DOI] [PubMed] [Google Scholar]
  11. Rubin P. C., McLean K., Reid J. L. Endogenous opioids and baroreflex control in humans. Hypertension. 1983 Jul-Aug;5(4):535–538. doi: 10.1161/01.hyp.5.4.535. [DOI] [PubMed] [Google Scholar]
  12. Rubin P., Blaschke T. F., Guilleminault C. Effect of naloxone, a specific opioid inhibitor, on blood pressure fall during sleep. Circulation. 1981 Jan;63(1):117–121. doi: 10.1161/01.cir.63.1.117. [DOI] [PubMed] [Google Scholar]
  13. Shepherd A. N., Campbell B. C., Reid J. L. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):381–387. doi: 10.1097/00005344-198205000-00007. [DOI] [PubMed] [Google Scholar]
  14. Skinner S. L. Improved assay methods for renin "concentration" and "activity" in human plasma. Methods using selective denaturation of renin substrate. Circ Res. 1967 Apr;20(4):391–402. doi: 10.1161/01.res.20.4.391. [DOI] [PubMed] [Google Scholar]
  15. Stine S. M., Yang H. Y., Costa E. Inhibition of in situ metabolism of [3H](met5)-enkephalin and potentiation of (met5)-enkephalin analgesia by captopril. Brain Res. 1980 Apr 21;188(1):295–299. doi: 10.1016/0006-8993(80)90581-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES